At last follow-up visit, angiotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor type 1 (AT1) antagonists were prescribed in 31/49 (63%) patients for treatment of reduced RV ejection fraction/heart failure. The gene discussed is ACE; the disease is heart failure.